Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain

Daniela Salvemini, Timothy Doyle, Michaela Kress, Grant Nicol

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Approximately 20% of the population in Western countries suffers from chronic pain syndromes for which treatments are frequently insufficient or non-existent. In particular, chronic pain management with opiate/narcotic analgesics is often hampered by the development of analgesic tolerance and hyperalgesia, necessitating escalating doses to achieve pain relief. There is a major need for renewed focus on novel targets that will be effective in both neuropathic and inflammatory pain. Compelling evidence implicates ceramide-to-sphingosine 1-phosphate (S1P) pathways as contributors to pain of diverse etiologies. Moreover, S1P and its receptors are emerging as important neuronal and immune cell regulators interacting at several sites in the pain pathway. It is therefore timely and important to critically evaluate the pharmacological basis for targeting the ceramide-to-S1P pathway as an approach to pain management.

Original languageEnglish
Pages (from-to)110-118
Number of pages9
JournalTrends in Pharmacological Sciences
Volume34
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Ceramides
Opiate Alkaloids
Lysosphingolipid Receptors
Pain Management
Pain
Chronic Pain
Narcotics
Analgesics
Hyperalgesia
Neuralgia
Therapeutics
Pharmacology
Population
sphingosine 1-phosphate

Keywords

  • FTY720
  • inflammation
  • multiple sclerosis
  • nociception

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. / Salvemini, Daniela; Doyle, Timothy; Kress, Michaela; Nicol, Grant.

In: Trends in Pharmacological Sciences, Vol. 34, No. 2, 02.2013, p. 110-118.

Research output: Contribution to journalArticle

Salvemini, Daniela ; Doyle, Timothy ; Kress, Michaela ; Nicol, Grant. / Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. In: Trends in Pharmacological Sciences. 2013 ; Vol. 34, No. 2. pp. 110-118.
@article{5ab23449a9764ce098afdcccf15bbb20,
title = "Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain",
abstract = "Approximately 20{\%} of the population in Western countries suffers from chronic pain syndromes for which treatments are frequently insufficient or non-existent. In particular, chronic pain management with opiate/narcotic analgesics is often hampered by the development of analgesic tolerance and hyperalgesia, necessitating escalating doses to achieve pain relief. There is a major need for renewed focus on novel targets that will be effective in both neuropathic and inflammatory pain. Compelling evidence implicates ceramide-to-sphingosine 1-phosphate (S1P) pathways as contributors to pain of diverse etiologies. Moreover, S1P and its receptors are emerging as important neuronal and immune cell regulators interacting at several sites in the pain pathway. It is therefore timely and important to critically evaluate the pharmacological basis for targeting the ceramide-to-S1P pathway as an approach to pain management.",
keywords = "FTY720, inflammation, multiple sclerosis, nociception",
author = "Daniela Salvemini and Timothy Doyle and Michaela Kress and Grant Nicol",
year = "2013",
month = "2",
doi = "10.1016/j.tips.2012.12.001",
language = "English",
volume = "34",
pages = "110--118",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain

AU - Salvemini, Daniela

AU - Doyle, Timothy

AU - Kress, Michaela

AU - Nicol, Grant

PY - 2013/2

Y1 - 2013/2

N2 - Approximately 20% of the population in Western countries suffers from chronic pain syndromes for which treatments are frequently insufficient or non-existent. In particular, chronic pain management with opiate/narcotic analgesics is often hampered by the development of analgesic tolerance and hyperalgesia, necessitating escalating doses to achieve pain relief. There is a major need for renewed focus on novel targets that will be effective in both neuropathic and inflammatory pain. Compelling evidence implicates ceramide-to-sphingosine 1-phosphate (S1P) pathways as contributors to pain of diverse etiologies. Moreover, S1P and its receptors are emerging as important neuronal and immune cell regulators interacting at several sites in the pain pathway. It is therefore timely and important to critically evaluate the pharmacological basis for targeting the ceramide-to-S1P pathway as an approach to pain management.

AB - Approximately 20% of the population in Western countries suffers from chronic pain syndromes for which treatments are frequently insufficient or non-existent. In particular, chronic pain management with opiate/narcotic analgesics is often hampered by the development of analgesic tolerance and hyperalgesia, necessitating escalating doses to achieve pain relief. There is a major need for renewed focus on novel targets that will be effective in both neuropathic and inflammatory pain. Compelling evidence implicates ceramide-to-sphingosine 1-phosphate (S1P) pathways as contributors to pain of diverse etiologies. Moreover, S1P and its receptors are emerging as important neuronal and immune cell regulators interacting at several sites in the pain pathway. It is therefore timely and important to critically evaluate the pharmacological basis for targeting the ceramide-to-S1P pathway as an approach to pain management.

KW - FTY720

KW - inflammation

KW - multiple sclerosis

KW - nociception

UR - http://www.scopus.com/inward/record.url?scp=84873410053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873410053&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2012.12.001

DO - 10.1016/j.tips.2012.12.001

M3 - Article

VL - 34

SP - 110

EP - 118

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 2

ER -